Fine‐tuning of the automated [18F]PSMA‐1007 radiosynthesis
Authors:
- 3 April 2019
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 62 (6) , 252-258
Abstract
Radiolabeled prostate‐specific membrane antigen (PSMA) targeting PET‐tracers have become desirable radiopharmaceuticals for the imaging of prostate cancer (PC). Recently, the PET radiotracer [18F]PSMA‐1007 was introduced as an alternative to [68Ga]Ga‐PSMA‐11, for staging and diagnosing biochemically recurrent PC. We incorporated a one‐step procedure for [18F]PSMA‐1007 radiosynthesis, using both Synthra RNplus and GE TRACERlab FxFN automated modules, in accordance with the recently described radiolabeling procedure. Although the adapted [18F]PSMA‐1007 synthesis resulted in repeatable radiochemical yields (55 ± 5%, NDC), suboptimal radiochemical purities of 87 ± 8% were obtained using both modules. As described here, modifications made to the radiolabeling and the solid‐phase extraction purification steps reduced synthesis time to 32 minutes and improved radiochemical purity to 96.10%, using both modules, without shearing the radiochemical yield.Keywords
This publication has 18 references indexed in Scilit:
- Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- Intraindividual Comparison of 18F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept StudyJournal of Nuclear Medicine, 2017
- 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2017
- 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617EJNMMI Research, 2017
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer ImagingJournal of Nuclear Medicine, 2016
- 18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617European Journal of Nuclear Medicine and Molecular Imaging, 2016
- PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesProstate Cancer and Prostatic Diseases, 2016
- The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor LesionsJournal of Nuclear Medicine, 2015
- Optimization of the preparation of fluorine‐18‐labeled steroid receptor ligands 16alpha‐[18F]fluoroestradiol (FES), [18F]fluoro furanyl norprogesterone (FFNP), and 16beta‐[18F]fluoro‐5alpha‐dihydrotestosterone (FDHT) as radiopharmaceuticalsJournal of Labelled Compounds and Radiopharmaceuticals, 2014